Alzheimer Disease Markers
General
Synonym/Acronym:
CSF tau protein and Beta-amyloid-42, AD, APP, PS-1, PS-2, ApoE4.
Rationale
To assist in evaluating for Alzheimer disease risk.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
(Method: Electrochemiluminescent immunoassay for Beta-amyloid-42 and tau protein, and polymerase chain reaction for detection of apolipoprotein E2, E3, E4 alleles as biochemical and genetic markers of Alzheimer disease [AD] risk. Scientific studies indicate that a combination of elevated tau protein and decreased Beta-amyloid-42 protein levels are consistent with the presence of AD.)
Beta-amyloid-42 | Greater than 1026 pg/mL (these levels correlate with negative findings in an amyloid PET scan) | ||||||||||||||||||||||||||||||||||||||||
Tau protein (total) | Less than or equal to 238 pg/mL | ||||||||||||||||||||||||||||||||||||||||
Phospho-Tau | Less than or equal to 21.7 pg/mL | ||||||||||||||||||||||||||||||||||||||||
ApoE 2–4 alleles | Homozygous Apo e3 (e3/e3) is the most commonly identified (normal) pattern; the ApoE4 allele is associated with increased risk of developing AD | ||||||||||||||||||||||||||||||||||||||||
The testing laboratory should be consulted for interpretation of results. |
Critical Findings and Potential Interventions
N/A
There's more to see -- the rest of this topic is available only to subscribers.